Lin R - Search Results

1

Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.

Lin TA, McCaw ZR, Koong A, Lin C, Abi Jaoude J, Patel R, Kouzy R, El Alam MB, Sherry AD, Noticewala SS, Fuller CD, Thomas CR Jr, Sun R, Lee JJ, Lin R, Yuan Y, Shyr Y, Meirson T, Ludmir EB. Lin TA, et al. Among authors: lin r, lin c. Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566. Clin Cancer Res. 2024. PMID: 39133081

2

Time-to-Event Bayesian Optimal Interval Design to Accelerate Phase I Trials.

Yuan Y, Lin R, Li D, Nie L, Warren KE. Yuan Y, et al. Among authors: lin r. Clin Cancer Res. 2018 Oct 15;24(20):4921-4930. doi: 10.1158/1078-0432.CCR-18-0246. Epub 2018 May 16. Clin Cancer Res. 2018. PMID: 29769209 Free PMC article.

3

TOP: Time-to-Event Bayesian Optimal Phase II Trial Design for Cancer Immunotherapy.

Lin R, Coleman RL, Yuan Y. Lin R, et al. J Natl Cancer Inst. 2020 Jan 1;112(1):38-45. doi: 10.1093/jnci/djz049. J Natl Cancer Inst. 2020. PMID: 30924863 Free PMC article.

4

Time-to-event model-assisted designs for dose-finding trials with delayed toxicity.

Lin R, Yuan Y. Lin R, et al. Biostatistics. 2020 Oct 1;21(4):807-824. doi: 10.1093/biostatistics/kxz007. Biostatistics. 2020. PMID: 30984972 Free PMC article.

5

On the relative efficiency of model-assisted designs: a conditional approach.

Lin R, Yuan Y. Lin R, et al. J Biopharm Stat. 2019;29(4):648-662. doi: 10.1080/10543406.2019.1632881. Epub 2019 Jun 29. J Biopharm Stat. 2019. PMID: 31258039 Free PMC article.

6

An adaptive trial design to optimize dose-schedule regimes with delayed outcomes.

Lin R, Thall PF, Yuan Y. Lin R, et al. Biometrics. 2020 Mar;76(1):304-315. doi: 10.1111/biom.13116. Epub 2019 Sep 19. Biometrics. 2020. PMID: 31273750 Free PMC article.

7

Keyboard design for phase I drug-combination trials.

Pan H, Lin R, Zhou Y, Yuan Y. Pan H, et al. Among authors: lin r. Contemp Clin Trials. 2020 May;92:105972. doi: 10.1016/j.cct.2020.105972. Epub 2020 Mar 7. Contemp Clin Trials. 2020. PMID: 32151751

8

Sample size re-estimation in adaptive enrichment design.

Lin R, Yang Z, Yuan Y, Yin G. Lin R, et al. Contemp Clin Trials. 2021 Jan;100:106216. doi: 10.1016/j.cct.2020.106216. Epub 2020 Nov 24. Contemp Clin Trials. 2021. PMID: 33246098

9

BOIN12: Bayesian Optimal Interval Phase I/II Trial Design for Utility-Based Dose Finding in Immunotherapy and Targeted Therapies.

Lin R, Zhou Y, Yan F, Li D, Yuan Y. Lin R, et al. JCO Precis Oncol. 2020 Nov 16;4:PO.20.00257. doi: 10.1200/PO.20.00257. eCollection 2020. JCO Precis Oncol. 2020. PMID: 33283133 Free PMC article.

10

BOIN Suite: A Software Platform to Design and Implement Novel Early-Phase Clinical Trials.

Zhou Y, Lin R, Kuo YW, Lee JJ, Yuan Y. Zhou Y, et al. Among authors: lin r. JCO Clin Cancer Inform. 2021 Jan;5:91-101. doi: 10.1200/CCI.20.00122. JCO Clin Cancer Inform. 2021. PMID: 33439726 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

6,893 results

Search Page

Filters